|
1
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008.PubMed/NCBI
|
|
2
|
Bade BC and Dela Cruz CS: Lung Cancer
2020: Epidemiology, Etiology, and Prevention. Clin Chest Med.
41:1–24. 2020.PubMed/NCBI
|
|
3
|
Hirsch FR and Lippman SM: Advances in the
biology of lung cancer chemoprevention. J Clin Oncol. 23:3186–3197.
2005.PubMed/NCBI
|
|
4
|
Kasymjanova G, Tran AT, Cohen V, Pepe C,
Sakr L, Small D, Agulnik JS and Jagoe RT: The use of a standardized
Chinese herbal formula in patients with advanced lung cancer: a
feasibility study. J Integr Med. 16:390–395. 2018.PubMed/NCBI
|
|
5
|
Dy GK and Adjei AA: Novel targets for lung
cancer therapy: Part I. J Clin Oncol. 20:2881–2894. 2002.PubMed/NCBI
|
|
6
|
Singhal S, Vachani A, Antin-Ozerkis D,
Kaiser LR and Albelda SM: Prognostic implications of cell cycle,
apoptosis, and angiogenesis biomarkers in non-small cell lung
cancer: A review. Clin Cancer Res. 11:3974–3986. 2005.PubMed/NCBI
|
|
7
|
Ghosh N, Chaki R, Mandal V and Mandal SC:
COX-2 as a target for cancer chemotherapy. Pharmacol Rep.
62:233–244, 2010.7. PubMed/NCBI
|
|
8
|
Gasparini G, Longo R, Sarmiento R and
Morabito A: Inhibitors of cyclo-oxygenase 2: A new class of
anticancer agents? Lancet Oncol. 4:605–615. 2003.PubMed/NCBI
|
|
9
|
Kalinski P: Regulation of immune responses
by prostaglandin E2. J Immunol. 188:21–28. 2012.PubMed/NCBI
|
|
10
|
Williams CS, Mann M and DuBois RN: The
role of cyclooxygenases in inflammation, cancer, and development.
Oncogene. 18:7908–7916. 1999.PubMed/NCBI
|
|
11
|
Liggett JL, Zhang X, Eling TE and Baek SJ:
Anti-tumor activity of non-steroidal anti-inflammatory drugs:
Cyclooxygenase-independent targets. Cancer Lett. 346:217–224.
2014.PubMed/NCBI
|
|
12
|
Katori M and Majima M: Cyclooxygenase-2:
Its rich diversity of roles and possible application of its
selective inhibitors. Inflamm Res. 49:367–392. 2000.PubMed/NCBI
|
|
13
|
Gungor H, Ilhan N and Eroksuz H: The
effectiveness of cyclooxygenase-2 inhibitors and evaluation of
angiogenesis in the model of experimental colorectal cancer. Biomed
Pharmacother. 102:221–229. 2018.PubMed/NCBI
|
|
14
|
Huang S and Sinicrope FA:
Celecoxib-induced apoptosis is enhanced by ABT-737 and by
inhibition of autophagy in human colorectal cancer cells.
Autophagy. 6:256–269. 2010.PubMed/NCBI
|
|
15
|
Liu M, Li CM, Chen ZF, Ji R, Guo QH, Li Q,
Zhang HL and Zhou YN: Celecoxib regulates apoptosis and autophagy
via the PI3K/Akt signaling pathway in SGC-7901 gastric cancer
cells. Int J Mol Med. 33:1451–1458. 2014.PubMed/NCBI
|
|
16
|
Kim N, Kim CH, Ahn DW, Lee KS, Cho SJ,
Park JH, Lee MK, Kim JS, Jung HC and Song IS: Anti-gastric cancer
effects of celecoxib, a selective COX-2 inhibitor, through
inhibition of Akt signaling. J Gastroenterol Hepatol. 24:480–487.
2009.PubMed/NCBI
|
|
17
|
Dai ZJ, Ma XB, Kang HF, Gao J, Min WL,
Guan HT, Diao Y, Lu WF and Wang XJ: Antitumor activity of the
selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer
in vitro and in vivo. Cancer Cell Int. 12:532012.PubMed/NCBI
|
|
18
|
Kim B, Kim J and Kim YS: Celecoxib induces
cell death on non-small cell lung cancer cells through endoplasmic
reticulum stress. Anat Cell Biol. 50:293–300. 2017.PubMed/NCBI
|
|
19
|
Schellhorn M, Haustein M, Frank M,
Linnebacher M and Hinz B: Celecoxib increases lung cancer cell
lysis by lymphokine-activated killer cells via upregulation of
ICAM-1. Oncotarget. 6:39342–39356. 2015.PubMed/NCBI
|
|
20
|
Bieniek J, Childress C, Swatski MD and
Yang W: COX-2 inhibitors arrest prostate cancer cell cycle
progression by down-regulation of kinetochore/centromere proteins.
Prostate. 74:999–1011. 2014.PubMed/NCBI
|
|
21
|
Katkoori VR, Manne K, Vital-Reyes VS,
Rodríguez-Burford C, Shanmugam C, Sthanam M, Manne U, Chatla C,
Abdulkadir SA and Grizzle WE: Selective COX-2 inhibitor (celecoxib)
decreases cellular growth in prostate cancer cell lines independent
of p53. Biotech Histochem. 88:38–46. 2013.PubMed/NCBI
|
|
22
|
Grösch S, Maier TJ, Schiffmann S and
Geisslinger G: Cyclooxygenase-2 (COX-2)-independent
anticarcinogenic effects of selective COX-2 inhibitors. J Natl
Cancer Inst. 98:736–747. 2006.PubMed/NCBI
|
|
23
|
Wu T, Leng J, Han C and Demetris AJ: The
cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt
and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer
Ther. 3:299–307. 2004.PubMed/NCBI
|
|
24
|
Tołoczko-Iwaniuk N, Dziemiańczyk-Pakieła
D, Nowaszewska BK, Celińska-Janowicz K and Miltyk W: Celecoxib in
cancer therapy and prevention - review. Curr Drug Targets.
20:302–315. 2019.PubMed/NCBI
|
|
25
|
Bryceson YT and Ljunggren HG: Tumor cell
recognition by the NK cell activating receptor NKG2D. Eur J
Immunol. 38:2957–2961. 2008.PubMed/NCBI
|
|
26
|
Waldhauer I and Steinle A: NK cells and
cancer immunosurveillance. Oncogene. 27:5932–5943. 2008.PubMed/NCBI
|
|
27
|
Raulet DH: Roles of the NKG2D
immunoreceptor and its ligands. Nat Rev Immunol. 3:781–790.
2003.PubMed/NCBI
|
|
28
|
Dhar P and Wu JD: NKG2D and its ligands in
cancer. Curr Opin Immunol. 51:55–61. 2018.PubMed/NCBI
|
|
29
|
Kim SJ, Ha GH, Bae JH, Kim GR, Son CH,
Park YS, Yang K, Oh SO, Kim SH and Kang CD: COX-2- and endoplasmic
reticulum stress-independent induction of ULBP-1 and enhancement of
sensitivity to NK cell-mediated cytotoxicity by celecoxib in colon
cancer cells. Exp Cell Res. 330:451–459. 2015.PubMed/NCBI
|
|
30
|
Reckamp KL: Molecular Targets Beyond the
Big 3. Thorac Surg Clin. 30:157–164. 2020.PubMed/NCBI
|
|
31
|
Kyriakis JM and Avruch J: Protein kinase
cascades activated by stress and inflammatory cytokines. BioEssays.
18:567–577. 1996.PubMed/NCBI
|
|
32
|
Soriani A, Borrelli C, Ricci B, Molfetta
R, Zingoni A, Fionda C, Carnevale S, Abruzzese MP, Petrucci MT,
Ricciardi MR, et al: p38 MAPK differentially controls NK activating
ligands at transcriptional and post-transcriptional level on
multiple myeloma cells. OncoImmunology. 6:e12645642016.PubMed/NCBI
|
|
33
|
Chen XH, Lu LL, Ke HP, Liu ZC, Wang HF,
Wei W, Qi YF, Wang HS, Cai SH and Du J: The TGF-β-induced
up-regulation of NKG2DLs requires AKT/GSK-3β-mediated stabilization
of SP1. J Cell Mol Med. 21:860–870. 2017.PubMed/NCBI
|
